IL-17 Biomarker Selection for Targeted Hidradenitis Suppurativa Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IL-17-dependent conditions, particularly hidradenitis suppurativa (HS), are inadequate in early diagnosis, personalized treatment, and managing disease progression, leading to irreversible tissue damage due to the inability to accurately assess disease severity and respond to therapeutic interventions.
Innovation Solution
Administering an IL-17A-and/or IL-17F-inhibiting nanobody, such as sonelokimab, to patients identified by elevated levels of specific biomarkers like IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, etc., in tissue or blood samples, to inhibit IL-17 activity and prevent tissue destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional IL-17A blocking monoclonal antibody therapies are used, then IL-17A activity is inhibited, but IL-17F/F dimer activity remains unaffected leading to inadequate treatment response
Solution Approach 1:
The patent applies universality by developing nanobodies that can recognize and bind to multiple IL-17 family members (IL-17A, IL-17F, and their dimers) with a single therapeutic agent. This multi-functional approach ensures comprehensive coverage of the IL-17 pathway, preventing both IL-17A/A and IL-17F/F dimers from binding to their receptors, thereby resolving the limitation of traditional therapies that only targeted IL-17A
Solution Approach 2:
The patent employs parameter changes by transitioning from traditional monoclonal antibodies to nanobodies with altered binding characteristics. The nanobodies exhibit enhanced ability to recognize conserved epitopes across different IL-17 family members, changing the binding parameter from IL-17A-specific to broadly cross-reactive with IL-17A, IL-17F, and their dimers, thereby improving treatment reliability
2Reliability
If treatment is initiated without biomarker-based patient selection, then all patients receive therapy, but treatment effectiveness is reduced due to inability to identify responders
Solution Approach 1:
The patent applies preliminary action by implementing biomarker assessment (IL-17A, IL-17F, LCN2 levels) before initiating therapy. This pre-treatment evaluation identifies patients with elevated IL-17 pathway activity who are most likely to respond to IL-17 inhibitor therapy, allowing clinicians to select appropriate candidates in advance and avoid ineffective treatment in non-responders
Solution Approach 2:
The patent employs feedback mechanisms by using biomarker levels as indicators to guide treatment decisions. Elevated baseline levels of IL-17A, IL-17F, or LCN2 provide feedback that the patient has active IL-17-dependent disease and is likely to respond to therapy, while lack of biomarker elevation suggests alternative treatment approaches should be considered
3Loss of time
If diagnosis is delayed until standard clinical criteria are met, then conventional treatment can be initiated, but irreversible tissue damage has already occurred
Solution Approach 1:
The patent applies preliminary action by enabling early diagnosis through detection of elevated biomarkers (IL-17A, IL-17F, LCN2) before irreversible tissue damage occurs. This allows clinicians to identify patients with active IL-17-dependent inflammation at an early stage and initiate protective therapy before permanent damage ensues
Solution Approach 2:
The patent employs preliminary anti-action by using biomarker detection to trigger early intervention with IL-17 inhibitors. By identifying elevated IL-17 pathway activity through biomarkers before clinical manifestations become severe, the treatment prevents the harmful progression of inflammation that would otherwise lead to irreversible tissue destruction
4Adaptability or versatility
If comprehensive biomarker panels are used for patient selection, then treatment personalization is improved, but diagnostic complexity and cost increase
Solution Approach 1:
The patent applies segmentation by dividing the diagnostic approach into a focused panel of key biomarkers (IL-17A, IL-17F, LCN2) rather than assessing all possible inflammatory markers. This segmented approach targets the specific IL-17 pathway components most relevant to treatment response, simplifying the diagnostic process while maintaining personalization capability
Solution Approach 2:
The patent employs local quality by concentrating diagnostic resources on measuring specific biomarkers (IL-17A, IL-17F, LCN2) that have direct relevance to IL-17 inhibitor therapy response. Rather than performing comprehensive inflammatory profiling, the approach focuses locally on the critical markers that predict treatment benefit, reducing complexity while preserving personalization
Data Source
AI summary
Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.